cancer cells and Enhance Efficacy
- HOME
- R&D
- PINOT-ADC™
Next Generation ADC Platform
PINOT-ADC™ is a next-generation ADC anticancer drug platform technology that uses an independent drug (Payload) and linker
that overcome the limitations of existing ADC drugs.
Based on the PINOT-ADC™ technology, we are jointly conducting research and development of a number of candidate substances such as
the best-in-class ADC anticancer drug (PBX-001) targeting solid cancer Trop2 with various partner companies.
Distinction and Competitive Advantage
Topoisomerase 1 inhibitor payload
On top of Top1 inhibition, the payload can also suppress anti-apoptotic protein expression and induce innate immune response to exert a powerful anti-cancer efficacy
Bystander effect is optimized via cell membrane permeability
Highly safe with minimal side effects or toxicity in the normal tissue
Resistance can be overcome by evading ABCG2, a protein which acts as drug efflux pump
Cleavable linker(Acid/Enzyme)
Highly scalable and can be customized according to each target’s property
Rapid activation and drug release in the tumor cells
High hydrophilicity minimizes absorption into normal tissue
Specific to a given target
Joint research with both domestic and global antibody developers
Platform is applicable across wide-range of drug delivery modality, such as aptamer, repebody, etc.
PINOT-ADC™ Platform
Clinical trial status
Project/Target | Indication | Development Stage Discovery
Preclinical
Phase 1
Phase 2
Phase 3
|
Antibody Provider |
Licensee | |
---|---|---|---|---|---|
ADC platform Pipeline |
PBX-CT01 (Undisclosed) |
Undisclosed | |||
ADC Products Pipeline |
PBX-001 (Trop2) |
Triple Negative Breast Cancer (TNBC), lung cancer, bladder cancer, etc. | Sacituzumab Biosimilar |
- | |
PBX-002 (Undisclosed) |
Triple Negative Breast Cancer (TNBC), etc. |
Undisclosed | - | ||
PBX-003 (EGFR) |
Colorectal cancer, lung cancer, head and neck cancer, etc. |
- |